DFTX (Definium Therapeutics) Momentum Rank: 3 (As of Aug. 18, 2026) — 63% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DFTX Definium Therapeutics Inc DFTX
28 GF Score
Price $45.32
! 5 Warning Signs
View Full Analysis

What is Definium Therapeutics Momentum Rank?

Definium Therapeutics DFTX +6.17% 28 Momentum Rank is 3 as of Aug. 18, 2026, which is 63% below its 10-year median of 8.00. GuruFocus rates DFTX with a GF Score™ of 28/100. The stock has 5 warning signs investors should review.

Definium Therapeutics has the Momentum Rank of 3.

Momentum Rank measures the strength and persistence of a stock's price movement over time, rated on a scale of 1 to 10.

For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.

Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.

For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.

A higher score reflects strong price momentum and indicates greater potential for superior performance. Conversely, a lower score indicates that momentum is either too high or too low, and stocks tend to underperform.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Definium Therapeutics Momentum Rank Related Terms

DFTX vs SRRK, DNTH, ORKA: Momentum Rank Comparison

For the Biotechnology subindustry, Definium Therapeutics's Momentum Rank, along with its competitors' market caps and Momentum Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Definium Therapeutics Momentum Rank vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Definium Therapeutics's Momentum Rank distribution charts can be found below:

* The bar in red indicates where Definium Therapeutics's Momentum Rank falls into.


DFTX
28GF Score
Definium Therapeutics Inc DFTX
Momentum Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Momentum Rank →
What does a Momentum Rank of 3 mean?
Definium Therapeutics (DFTX) has a Momentum Rank of 3 as of Aug. 18, 2026. Momentum Rank is determined using the standardized momentum ratio, measuring the speed and velocity of price changes in a stock. View historical data on Definium Therapeutics and its competitors. This is 63% below median its historical median of 8.00. Over the past decade, Definium Therapeutics' Momentum Rank has ranged from 3.00 to 10.00.
Is Definium Therapeutics' Momentum Rank too high?
Definium Therapeutics' current Momentum Rank of 3 is 63% below median its 10-year median of 8.00. Over the past 10 years, this metric has ranged from a low of 3.00 to a high of 10.00. Overall, Definium Therapeutics has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Definium Therapeutics' Momentum Rank compare to SRRK and DNTH?
Definium Therapeutics' Momentum Rank of 3 can be compared against companies in the Biotechnology industry. Historically, Definium Therapeutics' own Momentum Rank has ranged from 3.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Momentum Rank for a Biotechnology company?
A good Momentum Rank depends on the Biotechnology industry context. However, Momentum Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Momentum Rank mean?
A high Momentum Rank can signal that a stock is expensive relative to its fundamentals. Momentum Rank is determined using the standardized momentum ratio, measuring the speed and velocity of price changes in a stock. View historical data on Definium Therapeutics and its competitors. Definium Therapeutics's current Momentum Rank is 3, which is 63% below median its own 10-year median of 8.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Definium Therapeutics stock overvalued right now?
Definium Therapeutics (DFTX) has a current Momentum Rank of 3. The current Momentum Rank is 3, which is 63% below median its 10-year median of 8.00. Definium Therapeutics' overall GF Score™ is 28/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Momentum Rank calculated?
Momentum Rank is calculated from a company's financial statements. For Definium Therapeutics (DFTX), the current Momentum Rank is 3 as of Aug. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Definium Therapeutics Business Description

Other Exchanges MMQ0:Germany
Address One World Trade Center, Suite 8500, New York, NY, USA, 10007
Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company operates in one reportable segment relating to the research and development of the company's neurological drug development platform.
28GF Score

Get the complete analysis for DFTX

Momentum Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$45.32
Price